Prevalence of Mullerian Anomalies in Infertile Women

January 8, 2019 updated by: Mahmoud Alalfy, Aljazeera Hospital

Prevalence of Mullerian Anomalies and PCO in Egyptian Women

  • Mullerian anomalies are congenital structural anomalies in the uterus .
  • Its prevalence is not uncommon .

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

  • PCO is very common in gynecological practice
  • Women with mullerian anomalies should be properly evaluated for other gynecological and urological problems

Study Type

Observational

Enrollment (Anticipated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Giza, Egypt
        • Recruiting
        • Algazeerah

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

- females with age between 20-42 years with primary infertility

Description

Inclusion Criteria:

  • females with age between 20-42 years with primary infertility

Exclusion Criteria:

  • females with age above 42 years or below 20 years females with secondary infertility

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the number of participants who will prove to have PCO
Time Frame: within 4 weeks
diagnosis of PCO by US and by FSH and LH levels
within 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Aljazeera Hospital

Collaborators

Kasr El Aini Hospital
National Research Centre, Egypt
misr Infertility centre ,Alaqsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 16, 2018

Primary Completion (Anticipated)

April 20, 2019

Study Completion (Anticipated)

April 25, 2019

Study Registration Dates

First Submitted

April 7, 2018

First Submitted That Met QC Criteria

April 12, 2018

First Posted (Actual)

April 13, 2018

Study Record Updates

Last Update Posted (Actual)

January 9, 2019

Last Update Submitted That Met QC Criteria

January 8, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • mullerian anomalies

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

we will publish the results which will be obtained from this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mullerian Anomaly of Uterus

Clinical Trials on 3D ultrasound

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe